Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:9053 |
Name | bladder carcinoma in situ |
Definition | An in situ carcinoma that is located_in the bladder. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation pre-malignant neoplasm in situ carcinoma bladder carcinoma in situ |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03091660 | Phase III | BCG Tokyo-172 Strain Solution BCG solution | Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer | Active, not recruiting | USA | 0 |
NCT03106610 | Phase I | Nivolumab | Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy | Terminated | USA | 0 |
NCT06390111 | Expanded access | Nadofaragene firadenovec | A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose. (ABLE-42) | Recruiting | USA | 0 |